Exhibit 99.1

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance

– Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion –

– Fourth-Quarter GAAP Earnings per Share of $1.61 and Non-GAAP Earnings per Share of $2.01 –

– Full-Year GAAP Earnings per Share of $5.07 and Non-GAAP Earnings per Share of $6.73 –

– Provides 2020 Guidance –

WILMINGTON, Mass.--(BUSINESS WIRE)--February 11, 2020--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2019 and provided guidance for 2020. For the quarter, revenue was $691.1 million, an increase of 14.9% from $601.5 million in the fourth quarter of 2018.

The acquisition of Citoxlab contributed 8.1% to consolidated fourth-quarter revenue growth. The impact of foreign currency translation reduced reported revenue growth by 0.6%. Excluding the effect of these items, organic revenue growth of 7.4% was driven by all three business segments, particularly the Discovery and Safety Assessment segment.

On a GAAP basis, fourth-quarter net income from continuing operations attributable to common shareholders was $80.3 million, an increase of 34.7% from net income of $59.7 million for the same period in 2018. Fourth-quarter diluted earnings per share on a GAAP basis were $1.61, an increase of 33.1% from $1.21 for the fourth quarter of 2018. The increases in GAAP net income and earnings per share were primarily driven by the Company’s venture capital investments, which represented a gain of $0.22 per share in the fourth quarter of 2019, compared to a loss of $0.10 per share for the same period in 2018. As previously disclosed, the Company’s venture capital investment performance has been excluded from non-GAAP results.

On a non-GAAP basis, net income from continuing operations was $100.1 million for the fourth quarter of 2019, an increase of 27.8% from $78.3 million for the same period in 2018. Fourth-quarter diluted earnings per share on a non-GAAP basis were $2.01, an increase of 26.4% from $1.59 per share for the fourth quarter of 2018. The non-GAAP net income and earnings per share increases were driven primarily by higher revenue, including the contribution from the Citoxlab acquisition, and operating margin improvement.


James C. Foster, Chairman, President and Chief Executive Officer, said, “We are very pleased with our strong fourth-quarter results, which generally exceeded our prior expectations. Fourth-quarter reported revenue growth was in the mid-teens, organic growth was in the high-single-digits, and earnings per share growth was firmly in double-digits. We believe the excellent finish to 2019 demonstrates that the breadth of our leading, early-stage portfolio is resonating with clients, as they increasingly choose to adopt our flexible and efficient outsourcing model. The investments we have made in our scientific capabilities, staff, and capacity, along with our efforts to build a more scalable organization to drive operating efficiency, are having the intended outcome. Our Company is the strongest it has ever been, and we are well positioned to drive profitable revenue growth in 2020 and in the future.”

“We are optimistic as we turn the page to 2020. Our outlook is based on execution of our strategy to strengthen our position as the leading, early-stage CRO and deliver value to our clients, while leveraging our position in robust end-markets, our attractive growth profile, and the incremental value that will be derived from achieving our stated goal of meaningful operating margin improvement,” Mr. Foster concluded.

Fourth-Quarter Segment Results

Research Models and Services (RMS)

Revenue for the RMS segment was $131.3 million in the fourth quarter of 2019, an increase of 2.2% from $128.5 million in the fourth quarter of 2018. Organic revenue growth was 2.8%, driven primarily by increased demand for research models in China, as well as higher revenue for research model services, principally the Insourcing Solutions (IS) business. The revenue increase was partially offset by lower sales volume for research models outside of China, particularly to large biopharmaceutical clients.

In the fourth quarter of 2019, the RMS segment’s GAAP operating margin decreased to 23.0% from 24.6% in the fourth quarter of 2018. On a non-GAAP basis, the operating margin decreased to 24.6% from 25.1% in the fourth quarter of 2018. The GAAP and non-GAAP operating margin decreases were driven primarily by the research models business outside of China.

Discovery and Safety Assessment (DSA)

Revenue for the DSA segment was $439.2 million in the fourth quarter of 2019, an increase of 22.6% from $358.2 million in the fourth quarter of 2018. The Citoxlab acquisition contributed 13.6% to DSA revenue growth. Organic revenue growth of 9.4% was primarily driven by robust demand from biotechnology clients across both the Safety Assessment and Discovery Services businesses.

In the fourth quarter of 2019, the DSA segment’s GAAP operating margin increased to 19.1% from 18.8% in the fourth quarter of 2018. The GAAP operating margin increase was driven primarily by operating leverage from higher revenue, partially offset by acquisition-related costs primarily related to the Citoxlab acquisition, including amortization of intangible assets. On a non-GAAP basis, the operating margin increased to 25.6% from 23.2% in the fourth quarter of 2018. The non-GAAP operating margin increase was driven primarily by operating leverage from higher revenue in both the Discovery Services and Safety Assessment businesses, as well as the Company’s continued focus on operating efficiency initiatives.


Manufacturing Support (Manufacturing)

Revenue for the Manufacturing segment was $120.6 million in the fourth quarter of 2019, an increase of 5.0% from $114.9 million in the fourth quarter of 2018. Organic revenue growth was 6.3%, driven primarily by continued robust demand for the Biologics Testing Solutions business. Revenue for the Microbial Solutions business also increased in the fourth quarter, but at a lower growth rate than in the first three quarters of 2019.

In the fourth quarter of 2019, the Manufacturing segment’s GAAP operating margin decreased to 34.4% from 35.1% in the fourth quarter of 2018. On a non-GAAP basis, the operating margin decreased to 37.2% from 37.4% in the fourth quarter of 2018. The GAAP and non-GAAP operating margin decreases were driven primarily by the Biologics Testing Solutions business.

Full-Year Results

For 2019, revenue increased by 15.7% to $2.62 billion from $2.27 billion in 2018. Organic revenue growth was 8.5%.

On a GAAP basis, net income from continuing operations attributable to common shareholders was $252.0 million in 2019, an increase of 12.1% from $224.9 million in 2018. Diluted earnings per share on a GAAP basis in 2019 were $5.07, an increase of 10.5% from $4.59 in 2018. On a GAAP basis, the Company recorded a gain from venture capital investments totaling $0.30 per share in 2019, compared to a gain of $0.23 in 2018.

On a non-GAAP basis, net income from continuing operations was $334.4 million in 2019, an increase of 17.8% from $283.9 million in 2018. Diluted earnings per share on a non-GAAP basis in 2019 were $6.73, an increase of 16.0% from $5.80 in 2018.

Research Models and Services (RMS)

For 2019, RMS revenue was $537.1 million, an increase of 3.3% from $519.7 million in 2018. Organic revenue growth was 5.2%.

On a GAAP basis, the RMS segment operating margin decreased to 24.9% in 2019 from 26.3% in 2018. On a non-GAAP basis, the operating margin decreased to 26.2% in 2019 from 26.9% in 2018.

Discovery and Safety Assessment (DSA)

For 2019, DSA revenue was $1.62 billion, an increase of 22.9% from $1.32 billion in 2018. Organic revenue growth was 9.1%.

On a GAAP basis, the DSA segment operating margin decreased to 16.0% in 2019 from 17.3% in 2018. On a non-GAAP basis, the operating margin increased to 22.0% in 2019 from 21.7% in 2018.


Manufacturing Support (Manufacturing)

For 2019, Manufacturing revenue was $465.1 million, an increase of 8.3% from $429.6 million in 2018. Organic revenue growth was 10.8%.

On a GAAP basis, the Manufacturing segment operating margin decreased to 31.3% in 2019 from 31.7% in 2018. On a non-GAAP basis, the operating margin decreased to 33.9% in 2019 from 34.2% in 2018.

2020 Guidance
The Company is providing the following revenue, earnings per share, and free cash flow guidance for 2020. Earnings per share in 2020 are expected to benefit from higher revenue, driven primarily by continued robust client demand, and meaningful operating margin improvement. Year-over-year earnings per share growth is expected to be 2.5% to 5.5% on a GAAP basis, and 10.5% to 13.0% on a non-GAAP basis in 2020.


2020 GUIDANCE




 


Revenue growth, reported




13.0% – 14.5%


Less: Contribution from acquisitions (1)




(4.0%) – (4.5%)


Less: Favorable impact of foreign exchange




(1.0%) – (1.5%)


Revenue growth, organic (2)




7.75% – 8.75%


GAAP EPS estimate (3)




$5.20 – $5.35


Amortization of intangible assets (4)




$1.65 – $1.70


Charges related to global efficiency initiatives (5)




<$0.05


Acquisition-related adjustments (6)




~$0.25


Other items (7)




$0.25 – $0.32


Non-GAAP EPS estimate




$7.45 – $7.60


Free cash flow (8)




$350 – $360 million

Footnotes to Guidance Table:

(1) The contribution from acquisitions reflects only those acquisitions that have been completed.

(2) Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign currency translation.

(3) GAAP EPS guidance does not include an estimate for future gains or losses from venture capital investments. Potential gains or losses are expected in 2020, but the Company does not forecast the future performance of its venture capital investments. Any future gains or losses would be excluded from non-GAAP results.

(4) Amortization of intangible assets includes an estimate of $0.30-$0.35 for the impact of the HemaCare acquisition because the preliminary purchase price allocation has not been completed.

(5) These charges, which primarily include severance and other costs, relate primarily to the Company’s planned efficiency initiatives. Other projects in support of global productivity and efficiency initiatives are expected, but these charges reflect only the decisions that have already been finalized.

(6) These adjustments are related to the evaluation and integration of acquisitions, and primarily include transaction, advisory, and certain third-party integration costs, as well as certain costs associated with acquisition-related efficiency initiatives.

(7) These items primarily relate to charges of $0.15-$0.22 associated with the planned termination of the Company’s U.S. pension plan in the second half of 2020, as well as charges of approximately $0.10 associated with U.S. and international tax legislation that necessitated changes to the Company’s international financing structure.

(8) The reconciliation of the current 2020 free cash flow guidance is as follows: Cash flow from operating activities of $500-$510 million, less capital expenditures of approximately $150 million, equates to free cash flow of $350-$360 million.


Webcast
Charles River has scheduled a live webcast on Tuesday, February 11th, at 8:30 a.m. EST to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.

Non-GAAP Reconciliations/Discontinued Operations
The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release. In addition, the Company reports results from continuing operations, which exclude results of the Phase I clinical business that was divested in 2011. The Phase I business is reported as a discontinued operation.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, which exclude the amortization of intangible assets, and other charges related to our acquisitions; expenses associated with evaluating and integrating acquisitions and divestitures, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our efficiency initiatives; the write-off of deferred financing costs and fees related to debt financing; third-party costs associated with the remediation of unauthorized access into our information systems detected in March 2019; the non-cash tax benefit related to our international financing structure; charges related to the planned settlement of our U.S. pension plan; charges recorded in connection with the modification of our option to purchase equity in one of our joint ventures; and investment gains or losses associated with our venture capital investments. This press release also refers to our revenue in both a GAAP and non-GAAP basis: “constant currency,” which we define as reported revenue growth adjusted for the impact of foreign currency translation, and “organic revenue growth,” which we define as reported revenue growth adjusted for foreign currency translation, acquisitions, and divestitures. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. Commencing in the first quarter of 2019, we exclude the performance of our venture capital investments due to the determination that such investment gains or losses are not core to our overall operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition. Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company’s website at ir.criver.com.


Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding the projected future financial performance of Charles River and our specific businesses; the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to the impact of acquisitions, including the acquisition of HemaCare, on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and spending trends by our clients; the potential outcome of and impact to our business and financial operations due to litigation and legal proceedings; and Charles River’s future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, and enhanced efficiency initiatives. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the ability to successfully integrate businesses we acquire; risks and uncertainties associated with the unauthorized access into its information systems reported on April 30, 2019, including the timing and effectiveness of adding enhanced security features and monitoring procedures, the status and effectiveness of the ongoing remediation process, the percentage of clients affected by the unauthorized access, and the potential revenue and financial impact related to the incident; the ability to execute our efficiency initiatives on an effective and timely basis (including divestitures and site closures); the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; the impact of Brexit; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 13, 2019 and the Quarterly Report on Form 10-Q as filed on November 6, 2019, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.










 

SCHEDULE 1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands, except for per share data)










 



Three Months Ended

 

Twelve Months Ended




December 28, 2019

 

December 29, 2018

 

December 28, 2019

 

December 29, 2018










 
Service revenue

$

549,380

 


$

460,993

 


$

2,029,371

 


$

1,687,941

 

Product revenue

 

141,758

 


 

140,537

 


 

591,855

 


 

578,155

 

Total revenue

 

691,138

 


 

601,530

 


 

2,621,226

 


 

2,266,096

 

Costs and expenses:








Cost of services provided (excluding amortization of intangible assets)

 

357,636

 


 

306,241

 


 

1,371,699

 


 

1,150,371

 

Cost of products sold (excluding amortization of intangible assets)

 

71,188

 


 

68,872

 


 

291,216

 


 

275,658

 

Selling, general and administrative

 

129,598

 


 

106,918

 


 

517,622

 


 

443,854

 

Amortization of intangible assets

 

23,927

 


 

17,017

 


 

89,538

 


 

64,830

 

Operating income

 

108,789

 


 

102,482

 


 

351,151

 


 

331,383

 

Other income (expense):








Interest income

 

684

 


 

118

 


 

1,522

 


 

812

 

Interest expense

 

(24,362

)


 

(16,741

)


 

(60,882

)


 

(63,772

)

Other income (expense), net

 

20,454

 


 

(10,811

)


 

12,293

 


 

13,258

 

Income from continuing operations, before income taxes

 

105,565

 


 

75,048

 


 

304,084

 


 

281,681

 

Provision for income taxes

 

25,053

 


 

14,850

 


 

50,023

 


 

54,463

 

Income from continuing operations, net of income taxes

 

80,512

 


 

60,198

 


 

254,061

 


 

227,218

 

Income from discontinued operations, net of income taxes











1,506


Net income

 

80,512

 


 

60,198

 


 

254,061

 


 

228,724

 

Less: Net income attributable to noncontrolling interests

 

164

 


 

533

 


 

2,042

 


 

2,351

 

Net income attributable to common shareholders

$

80,348

 


$

59,665

 


$

252,019

 


$

226,373

 










 
Earnings per common share








Basic:








Continuing operations attributable to common shareholders

$

1.64

 


$

1.24

 


$

5.17

 


$

4.69

 

Discontinued operations

$



$



$



$

0.03


Net income attributable to common shareholders

$

1.64

 


$

1.24

 


$

5.17

 


$

4.72

 

Diluted:








Continuing operations attributable to common shareholders

$

1.61

 


$

1.21

 


$

5.07

 


$

4.59

 

Discontinued operations

$



$



$



$

0.03


Net income attributable to common shareholders

$

1.61

 


$

1.21

 


$

5.07

 


$

4.62

 










 
Weighted-average number of common shares outstanding:








Basic

 

48,875

 


 

48,143

 


 

48,730

 


 

47,947

 

Diluted

 

49,867

 


 

49,210

 


 

49,693

 


 

49,018

 


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


 
SCHEDULE 2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands)






 


December 28, 2019
December 29, 2018
Assets





Current assets:





Cash and cash equivalents

$

238,014

 


$

195,442

 

Trade receivables, net

 

514,033

 


 

472,248

 

Inventories

 

160,660

 


 

127,892

 

Prepaid assets

 

52,588

 


 

53,447

 

Other current assets

 

56,030

 


 

48,807

 

Total current assets

 

1,021,325

 


 

897,836

 

Property, plant and equipment, net

 

1,044,128

 


 

932,877

 

Operating lease right-of-use assets, net

 

140,085

 



Goodwill

 

1,540,565

 


 

1,247,133

 

Client relationships, net

 

613,573

 


 

537,945

 

Other intangible assets, net

 

75,840

 


 

72,943

 

Deferred tax assets

 

44,659

 


 

23,386

 

Other assets

 

212,615

 


 

143,759

 

Total assets

$

4,692,790

 


$

3,855,879

 







 
Liabilities, Redeemable Noncontrolling Interests and Equity





Current liabilities:





Current portion of long-term debt and finance leases

$

38,545

 


$

31,416

 

Accounts payable

 

111,498

 


 

66,250

 

Accrued compensation

 

158,617

 


 

137,212

 

Deferred revenue

 

171,805

 


 

145,139

 

Accrued liabilities

 

139,118

 


 

106,925

 

Other current liabilities

 

90,598

 


 

71,280

 

Total current liabilities

 

710,181

 


 

558,222

 

Long-term debt, net and finance leases

 

1,849,666

 


 

1,636,598

 

Operating lease right-of-use liabilities

 

116,252

 



Deferred tax liabilities

 

167,283

 


 

143,635

 

Other long-term liabilities

 

182,933

 


 

179,121

 

Total liabilities

 

3,026,315

 


 

2,517,576

 

Redeemable noncontrolling interests

 

28,647

 


 

18,525

 

Equity:





Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding



Common stock, $0.01 par value; 120,000 shares authorized; 48,936 shares issued and 48,936 shares outstanding as of December 28, 2019 and 48,210 shares issued and 48,209 shares outstanding as of December 29, 2018

 

489

 


 

482

 

Additional paid-in capital

 

1,531,785

 


 

1,447,512

 

Retained earnings

 

280,329

 


 

42,096

 

Treasury stock, at cost, 0 and 1 share as of December 28, 2019 and December 29, 2018, respectively


 

(55

)

Accumulated other comprehensive loss

 

(178,019

)


 

(172,703

)

Total equity attributable to common shareholders

 

1,634,584

 


 

1,317,332

 

Noncontrolling interest

 

3,244

 


 

2,446

 

Total equity

 

1,637,828

 


 

1,319,778

 

Total liabilities, redeemable noncontrolling interests and equity

$

4,692,790

 


$

3,855,879

 


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

 
SCHEDULE 3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)






 



Twelve Months Ended



December 28, 2019
December 29, 2018






 
Cash flows relating to operating activities





Net income

$

254,061

 


$

228,724

 

Less: Income (loss) from discontinued operations, net of income taxes



 

1,506

 

Income from continuing operations, net of income taxes

 

254,061

 


 

227,218

 

Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:





Depreciation and amortization

 

198,095

 


 

161,779

 

Stock-based compensation

 

57,271

 


 

47,346

 

Deferred income taxes

 

(21,895

)


 

(9,702

)

Gain on venture capital investments

 

(20,706

)


 

(15,928

)

Other, net

 

7,931

 


 

15,613

 

Changes in assets and liabilities:





Trade receivables, net

 

(8,323

)


 

(21,196

)

Inventories

 

(21,399

)


 

(13,338

)

Accounts payable

 

29,775

 


 

(12,732

)

Accrued compensation

 

3,394

 


 

31,616

 

Long-term payable on Transition Tax



 

(8,974

)

Deferred revenue

 

(3,620

)


 

36,072

 

Customer contract deposits

 

(10,898

)


 

28,115

 

Other assets and liabilities, net

 

17,250

 


 

(24,749

)

Net cash provided by operating activities

 

480,936

 


 

441,140

 

Cash flows relating to investing activities





Acquisition of businesses and assets, net of cash acquired

 

(515,701

)


 

(824,868

)

Capital expenditures

 

(140,514

)


 

(140,054

)

Purchases of investments and contributions to venture capital investments

 

(22,341

)


 

(25,125

)

Proceeds from sale of investments

 

942

 


 

35,849

 

Other, net

 

(3,888

)


 

(805

)

Net cash used in investing activities

 

(681,502

)


 

(955,003

)

Cash flows relating to financing activities





Proceeds from long-term debt and revolving credit facility

 

3,358,461

 


 

2,755,028

 

Proceeds from exercises of stock options

 

34,546

 


 

37,657

 

Payments on long-term debt, revolving credit facility, and finance lease obligations

 

(3,124,588

)


 

(2,201,003

)

Payments on debt financing costs

 

(6,593

)


 

(18,337

)

Purchase of treasury stock

 

(18,087

)


 

(13,846

)

Other, net

 

(11,802

)


 

(1,440

)

Net cash provided by financing activities

 

231,937

 


 

558,059

 

Discontinued operations





Net cash used in operating activities from discontinued operations



 

(3,735

)

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

11,357

 


 

(9,474

)

Net change in cash, cash equivalents, and restricted cash

 

42,728

 


 

30,987

 

Cash, cash equivalents, and restricted cash, beginning of period

 

197,318

 


 

166,331

 

Cash, cash equivalents, and restricted cash, end of period

$

240,046

 


$

197,318

 







 
Supplemental cash flow information:

$

238,014

 


$

195,442

 

Cash and cash equivalents

 

431

 


 

465

 

Restricted cash included in Other current assets

 

1,601

 


 

1,411

 

Restricted cash included in Other assets

$

240,046

 


$

197,318

 

Cash, cash equivalents, and restricted cash, end of period











 
Cash paid for income taxes

$

54,060

 


$

67,600

 

Cash paid for interest

$

67,813

 


$

47,540

 

Non-cash investing and financing activities:





Additions to property, plant and equipment, net

$

21,447

 


$

18,212

 

Assets acquired under finance leases

$

4,819

 


$

1,473

 


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

 












 
SCHEDULE 4
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1)
(in thousands, except percentages)

 












 

 
Three Months Ended
Twelve Months Ended

 
December 28, 2019
December 29, 2018
December 28, 2019
December 29, 2018
Research Models and Services  













Revenue  

$

131,317

 


$

128,487

 


$

537,089

 


$

519,682

 

Operating income  

 

30,183

 


 

31,575

 


 

133,912

 


 

136,468

 

Operating income as a % of revenue  

 

23.0

%


 

24.6

%


 

24.9

%


 

26.3

%

Add back:  













Amortization related to acquisitions  

 

339

 


 

383

 


 

1,381

 


 

1,585

 

Severance  

 

1,000

 


 

353

 


 

2,106

 


 

1,161

 

Acquisition related adjustments (2)  



 

(23

)


 

2,201

 


 

(23

)

Site consolidation costs, impairments and other items  

 

786

 





 

1,043

 


 

822

 

Total non-GAAP adjustments to operating income  

$

2,125

 


$

713

 


$

6,731

 


$

3,545

 

Operating income, excluding non-GAAP adjustments  

$

32,308

 


$

32,288

 


$

140,643

 


$

140,013

 

Non-GAAP operating income as a % of revenue  

 

24.6

%


 

25.1

%


 

26.2

%


 

26.9

%


 












 
Depreciation and amortization  

$

4,999

 


$

4,904

 


$

19,197

 


$

19,469

 

Capital expenditures  

$

12,010

 


$

17,067

 


$

26,989

 


$

35,172

 


 












 
Discovery and Safety Assessment  













Revenue  

$

439,202

 


$

358,189

 


$

1,618,995

 


$

1,316,854

 

Operating income  

 

83,689

 


 

67,186

 


 

258,903

 


 

227,577

 

Operating income as a % of revenue  

 

19.1

%


 

18.8

%


 

16.0

%


 

17.3

%

Add back:  













Amortization related to acquisitions  

 

22,357

 


 

14,415

 


 

80,424

 


 

54,211

 

Severance  

 

4,778

 


 

41

 


 

7,311

 


 

1,014

 

Acquisition related adjustments (3)  

 

1,614

 


 

1,313

 


 

10,130

 


 

2,779

 

Site consolidation costs, impairments and other items  






 

(207

)


 

(117

)

Total non-GAAP adjustments to operating income  

$

28,749

 


$

15,769

 


$

97,658

 


$

57,887

 

Operating income, excluding non-GAAP adjustments  

$

112,438

 


$

82,955

 


$

356,561

 


$

285,464

 

Non-GAAP operating income as a % of revenue  

 

25.6

%


 

23.2

%


 

22.0

%


 

21.7

%


 












 
Depreciation and amortization  

$

39,908

 


$

29,714

 


$

151,139

 


$

112,976

 

Capital expenditures  

$

41,713

 


$

38,929

 


$

86,843

 


$

73,425

 


 












 
Manufacturing Support  













Revenue  

$

120,619

 


$

114,854

 


$

465,142

 


$

429,560

 

Operating income  

 

41,527

 


 

40,308

 


 

145,420

 


 

136,212

 

Operating income as a % of revenue  

 

34.4

%


 

35.1

%


 

31.3

%


 

31.7

%

Add back:  













Amortization related to acquisitions  

 

2,260

 


 

2,219

 


 

9,062

 


 

9,035

 

Severance  

 

1,102

 


 

357

 


 

1,651

 


 

1,227

 

Acquisition related adjustments (3)  

 

68

 


 

112

 


 

286

 


 

112

 

Site consolidation costs, impairments and other items  

 

(103

)





 

1,382

 


 

159

 

Total non-GAAP adjustments to operating income  

$

3,327

 


$

2,688

 


$

12,381

 


$

10,533

 

Operating income, excluding non-GAAP adjustments  

$

44,854

 


$

42,996

 


$

157,801

 


$

146,745

 

Non-GAAP operating income as a % of revenue  

 

37.2

%


 

37.4

%


 

33.9

%


 

34.2

%


 












 
Depreciation and amortization  

$

6,007

 


$

5,216

 


$

23,584

 


$

22,529

 

Capital expenditures  

$

9,318

 


$

10,592

 


$

23,617

 


$

23,323

 


 












 
Unallocated Corporate Overhead  

$

(46,610

)


$

(36,587

)


$

(187,084

)


$

(168,874

)

Add back:  













Severance and executive transition costs  

 

390

 





 

390

 


 

5,278

 

Acquisition related adjustments (3)  

 

3,634

 


 

618

 


 

26,822

 


 

16,316

 

Other items (4)  

 

657

 





 

2,065

 




Total non-GAAP adjustments to operating expense  

$

4,681

 


$

618

 


$

29,277

 


$

21,594

 

Unallocated corporate overhead, excluding non-GAAP adjustments  

$

(41,929

)


$

(35,969

)


$

(157,807

)


$

(147,280

)


 












 
Total  













Revenue  

$

691,138

 


$

601,530

 


$

2,621,226

 


$

2,266,096

 

Operating income  

 

108,789

 


 

102,482

 


 

351,151

 


 

331,383

 

Operating income as a % of revenue  

 

15.7

%


 

17.0

%


 

13.4

%


 

14.6

%

Add back:  













Amortization related to acquisitions  

 

24,956

 


 

17,017

 


 

90,867

 


 

64,831

 

Severance and executive transition costs  

 

7,270

 


 

751

 


 

11,458

 


 

8,680

 

Acquisition related adjustments (2)(3)  

 

5,316

 


 

2,020

 


 

39,439

 


 

19,184

 

Site consolidation costs, impairments and other items (4)  

 

1,340

 





 

4,283

 


 

864

 

Total non-GAAP adjustments to operating income  

$

38,882

 


$

19,788

 


$

146,047

 


$

93,559

 

Operating income, excluding non-GAAP adjustments  

$

147,671

 


$

122,270

 


$

497,198

 


$

424,942

 

Non-GAAP operating income as a % of revenue  

 

21.4

%


 

20.3

%


 

19.0

%


 

18.8

%


 












 
Depreciation and amortization  

$

51,833

 


$

41,581

 


$

198,095

 


$

161,779

 

Capital expenditures  

$

63,839

 


$

68,676

 


$

140,514

 


$

140,054

 

(1)


Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)


This amount represents a $2.2 million charge recorded during fiscal 2019 in connection with the modification of the option to purchase the remaining 8% equity interest in Vital River.

(3)


These adjustments are related to the evaluation and integration of acquisitions, which primarily include transaction, third-party integration, and certain compensation costs, and fair value adjustments associated with contingent consideration.

(4)


This amount relates to third-party costs, net of insurance reimbursements, associated with the remediation of the unauthorized access into the Company's information systems which was detected in March 2019.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.













 
SCHEDULE 5
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)(1)
(in thousands, except per share data)













 



Three Months Ended
Twelve Months Ended



December 28, 2019
December 29, 2018
December 28, 2019
December 29, 2018













 
Net income attributable to common shareholders

$

80,348

 


$

59,665

 


$

252,019

 


$

226,373

 

Less: Income from discontinued operations, net of income taxes







 

1,506

 

Net income from continuing operations attributable to common shareholders

 

80,348

 


 

59,665

 


 

252,019

 


 

224,867

 

Add back:












Non-GAAP adjustments to operating income (Refer to Schedule 4)

 

38,882

 


 

19,788

 


 

146,047

 


 

93,559

 

Write-off of deferred financing costs and fees related to debt financing

 

1,605

 




 

1,605

 


 

5,060

 

Venture capital (gains) losses

 

(14,983

)


 

6,832

 


 

(20,707

)


 

(15,928

)

Tax effect of non-GAAP adjustments:












Tax effect from U.S. Tax Reform (2)



 

(2,650

)




 

(5,450

)

Tax effect from divestiture of CDMO business







 

(1,000

)

Non-cash tax benefit related to international financing structure (3)

 

581

 




 

(19,787

)



Tax effect of the remaining non-GAAP adjustments

 

(6,368

)


 

(5,344

)


 

(24,811

)


 

(17,166

)

Net income from continuing operations attributable to common shareholders, excluding non-GAAP adjustments

$

100,065

 


$

78,291

 


$

334,366

 


$

283,942

 














 
Weighted average shares outstanding - Basic

 

48,875

 


 

48,143

 


 

48,730

 


 

47,947

 

Effect of dilutive securities:












Stock options, restricted stock units, performance share units and restricted stock

 

992

 


 

1,067

 


 

963

 


 

1,071

 

Weighted average shares outstanding - Diluted

 

49,867

 


 

49,210

 


 

49,693

 


 

49,018

 














 
Earnings per share from continuing operations attributable to common shareholders












Basic

$

1.64

 


$

1.24

 


$

5.17

 


$

4.69

 

Diluted

$

1.61

 


$

1.21

 


$

5.07

 


$

4.59

 














 
Basic, excluding non-GAAP adjustments

$

2.05

 


$

1.63

 


$

6.86

 


$

5.92

 

Diluted, excluding non-GAAP adjustments

$

2.01

 


$

1.59

 


$

6.73

 


$

5.80

 

(1)


Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)


This adjustment is related to the refinement of one-time charges associated with the enactment of U.S. Tax Reform related to the transition tax on unrepatriated earnings (also known as the toll tax), and the revaluation of U.S. federal net deferred tax liabilities.

(3)


This adjustment relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.









 
SCHEDULE 6
RECONCILIATION OF GAAP REVENUE GROWTH
TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1)









 
For the three months ended December 28, 2019

Total CRL
RMS Segment
DSA Segment
MS Segment









 
Revenue growth, reported

14.9

%


2.2

%


22.6

%


5.0

%

Decrease (increase) due to foreign exchange

0.6

%


0.6

%


0.4

%


1.3

%

Contribution from acquisitions

(8.1

)%


%


(13.6

)%


%

Non-GAAP revenue growth, organic (3)

7.4

%


2.8

%


9.4

%


6.3

%










 
For the twelve months ended December 28, 2019

Total CRL
RMS Segment
DSA Segment
MS Segment









 
Revenue growth, reported

15.7

%


3.3

%


22.9

%


8.3

%

Decrease (increase) due to foreign exchange

1.5

%


1.9

%


1.1

%


2.7

%

Contribution from acquisitions (2)

(8.7

)%


%


(14.9

)%


(0.2

)%

Non-GAAP revenue growth, organic (3)

8.5

%


5.2

%


9.1

%


10.8

%

(1)


Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)


The contribution from acquisitions reflects only completed acquisitions. Manufacturing Support includes an immaterial acquisition of an Australian Microbial Solutions business.

(3)


Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign exchange.

 

Contacts

Investor Contact:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com

Media Contact:
Amy Cianciaruso
Corporate Vice President,
Public Relations
781.222.6168
amy.cianciaruso@crl.com

View differences made from one to another to evaluate Charles River Laboratories International Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Charles River Laboratories International Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account